These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 10369945)

  • 1. Fluorodeoxyglucose positron emission tomography of soft tissue tumours: is a non-invasive determination of biological activity possible?
    Schulte M; Brecht-Krauss D; Heymer B; Guhlmann A; Hartwig E; Sarkar MR; Diederichs CG; Schultheiss M; Kotzerke J; Reske SN
    Eur J Nucl Med; 1999 Jun; 26(6):599-605. PubMed ID: 10369945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical value of [18-F]] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas.
    Schwarzbach MH; Dimitrakopoulou-Strauss A; Willeke F; Hinz U; Strauss LG; Zhang YM; Mechtersheimer G; Attigah N; Lehnert T; Herfarth C
    Ann Surg; 2000 Mar; 231(3):380-6. PubMed ID: 10714631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma.
    Nieweg OE; Pruim J; van Ginkel RJ; Hoekstra HJ; Paans AM; Molenaar WM; Koops HS; Vaalburg W
    J Nucl Med; 1996 Feb; 37(2):257-61. PubMed ID: 8667056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of soft tissue lesions suspicious for liposarcoma by F18-deoxyglucose (FDG) positron emission tomography (PET).
    Schwarzbach MH; Dimitrakopoulou-Strauss A; Mechtersheimer G; Hinz U; Willeke F; Cardona S; Attigah N; Strauss LG; Herfarth C; Lehnert T
    Anticancer Res; 2001; 21(5):3609-14. PubMed ID: 11848531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 11C-choline PET for the detection of bone and soft tissue tumours in comparison with FDG PET.
    Zhang H; Tian M; Oriuchi N; Higuchi T; Watanabe H; Aoki J; Tanada S; Endo K
    Nucl Med Commun; 2003 Mar; 24(3):273-9. PubMed ID: 12612468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A PET study of 18FDG uptake in soft tissue masses.
    Lodge MA; Lucas JD; Marsden PK; Cronin BF; O'Doherty MJ; Smith MA
    Eur J Nucl Med; 1999 Jan; 26(1):22-30. PubMed ID: 9933658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET imaging of musculoskeletal tumours with fluorine-18 alpha-methyltyrosine: comparison with fluorine-18 fluorodeoxyglucose PET.
    Watanabe H; Inoue T; Shinozaki T; Yanagawa T; Ahmed AR; Tomiyoshi K; Oriuchi N; Tokunaga M; Aoki J; Endo K; Takagishi K
    Eur J Nucl Med; 2000 Oct; 27(10):1509-17. PubMed ID: 11083540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Grading of tumors and tumorlike lesions of bone: evaluation by FDG PET.
    Schulte M; Brecht-Krauss D; Heymer B; Guhlmann A; Hartwig E; Sarkar MR; Diederichs CG; Von Baer A; Kotzerke J; Reske SN
    J Nucl Med; 2000 Oct; 41(10):1695-701. PubMed ID: 11038000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of several FDG PET parameters for prediction of soft tissue tumour grade at primary diagnosis and recurrence.
    Fendler WP; Chalkidis RP; Ilhan H; Knösel T; Herrmann K; Issels RD; Bartenstein P; Cyran CC; Lindner LH; Hacker M
    Eur Radiol; 2015 Aug; 25(8):2214-21. PubMed ID: 25693667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of F18-deoxyglucose positron emission tomography (FDG-PET) to assess the nature of neurogenic tumours.
    Cardona S; Schwarzbach M; Hinz U; Dimitrakopoulou-Strauss A; Attigah N; Mechtersheimer section sign G; Lehnert T
    Eur J Surg Oncol; 2003 Aug; 29(6):536-41. PubMed ID: 12875862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis.
    Bastiaannet E; Groen H; Jager PL; Cobben DC; van der Graaf WT; Vaalburg W; Hoekstra HJ
    Cancer Treat Rev; 2004 Feb; 30(1):83-101. PubMed ID: 14766127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Limitations of F-18-fluoro-2-deoxy-D-glucose Positron Emission Tomography to Differentiate Between Malignant and Benign Bone and Soft Tissue Tumors.
    Miwa S; Mochizuki T; Yamamoto N; Shirai T; Hayashi K; Takeuchi A; Inatani H; Igarashi K; Higuchi T; Abe K; Taniguchi Y; Aiba H; Ikeda H; Tsuchiya H
    Anticancer Res; 2018 Jul; 38(7):4065-4072. PubMed ID: 29970532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of soft-tissue lesions with (18)F-FDG PET/CT: initial results of a prospective trial.
    Leal AL; Etchebehere M; Santos AO; Kalaf G; Pacheco EB; Amstalden EM; Etchebehere EC
    Nucl Med Commun; 2014 Mar; 35(3):252-9. PubMed ID: 24300379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective evaluation of soft tissue masses and sarcomas using fluorodeoxyglucose positron emission tomography.
    Lucas JD; O'Doherty MJ; Cronin BF; Marsden PK; Lodge MA; McKee PH; Smith MA
    Br J Surg; 1999 Apr; 86(4):550-6. PubMed ID: 10215835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of FDG positron emission tomography for differentiation of unknown pulmonary lesions.
    Imdahl A; Jenkner S; Brink I; Nitzsche E; Stoelben E; Moser E; Hasse J
    Eur J Cardiothorac Surg; 2001 Aug; 20(2):324-9. PubMed ID: 11463551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of 11C-choline PET and FDG PET for the differential diagnosis of malignant tumors.
    Tian M; Zhang H; Oriuchi N; Higuchi T; Endo K
    Eur J Nucl Med Mol Imaging; 2004 Aug; 31(8):1064-72. PubMed ID: 15014903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDG-PET for preoperative differential diagnosis between benign and malignant soft tissue masses.
    Aoki J; Watanabe H; Shinozaki T; Takagishi K; Tokunaga M; Koyama Y; Sato N; Endo K
    Skeletal Radiol; 2003 Mar; 32(3):133-8. PubMed ID: 12605276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors.
    Shin DS; Shon OJ; Han DS; Choi JH; Chun KA; Cho IH
    Ann Nucl Med; 2008 Aug; 22(7):603-9. PubMed ID: 18756363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucose metabolic analysis of musculoskeletal tumours using 18fluorine-FDG PET as an aid to preoperative planning.
    Watanabe H; Shinozaki T; Yanagawa T; Aoki J; Tokunaga M; Inoue T; Endo K; Mohara S; Sano K; Takagishi K
    J Bone Joint Surg Br; 2000 Jul; 82(5):760-7. PubMed ID: 10963181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.